Eywa’s facility boasts the potential for a capacity expansion of up to two billion tablets or capsules annually. Credit: mkfilm/Shutterstock.com.

Biocon’s step-down, wholly owned subsidiary, Biocon Generics, has purchased the US-based oral solid dosage manufacturing facility of Eywa Pharma for a total consideration of $7.7m (Rs636.77m).

Located in Cranbury, New Jersey, the facility boasts the potential for a capacity expansion of up to two billion tablets or capsules annually.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The facility’s existing personnel will move to Biocon Generics as part of the transaction.

Biocon managing director and CEO Siddharth Mittal said: “The acquisition of this US FDA-approved facility, our first in the US, will complement Biocon’s existing manufacturing capabilities and strengthen our foothold in the US.

“The acquisition will also enable us to add oral solid dosage capacities for new products earlier than originally planned and ensure continuity of supply through the diversification of our manufacturing infrastructure.

See Also:

“Our focus will be on integrating the acquired facility expeditiously and expanding our portfolio in the region.”

In April 2023, the B3 plant of Biocon Biologics in Bengaluru, India, received GMP certification for manufacturing the biosimilar Bevacizumab. The Health Products Regulatory Authority in Ireland granted the approval.

The product is intended for the treatment of several cancers and a specific eye disease.

Biocon is also engaged in developing complex therapies for treating chronic conditions such as autoimmune, cancer and diabetes.

It also develops and market new biosimilars, biologics and complex small molecule APIs in India and various markets throughout the world.